Insights from 2023 IGCS Annual Meeting
IGCS 2023 Insights: "IGNITE Trial of Adavosertib Targeting Recurrent High-Grade Serous Ovarian Cancer With Cyclin E1 Over-Expression With & Without Gene Amplification"
By
Insights from 2023 IGCS Annual Meeting
FEATURING
George Au-Yeung
By
Insights from 2023 IGCS Annual Meeting
FEATURING
George Au-Yeung
Comments 0
Login to view comments.
Click here to Login
